---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-247017"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:00:23.874400+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MacroGenics CEO Scott Koenig to step down; search committee formed

## Summary
- Scott Koenig to depart as President and CEO effective Feb 28, 2025; will resign from Board on same date.
- Separation includes 24 months salary continuation, target bonus, COBRA, and accelerated vesting of 50% of unvested equity.
- Continuing as advisor until Feb 28, 2030, with continued vesting of remaining unvested equity awards.
- Board formed special committee and retained Heidrick & Struggles to identify new CEO.
- Company highlights strong balance sheet and pipeline of antibody-based cancer therapeutics.

## SEC filing metadata
- accession: 0001193125-24-247017
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000119312524247017/0001193125-24-247017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000119312524247017/d891583d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-247017
- JSON: https://secwatch.observer/filing/0001193125-24-247017.json
- Plain text: https://secwatch.observer/filing/0001193125-24-247017.txt

## Key facts
- Executive change
  Scott Koenig resigned as President and Chief Executive Officer at MACROGENICS INC.
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: On October 25, 2024, Dr. Scott Koenig, the President and Chief Executive Officer of MacroGenics, Inc. (the “ Company ”) and the Company entered into a separation and consulting agreement, dated October 25, 2024 (the “ Separation Agreement ”), which provides for the terms of Dr. Koenig’s separation from employment, effective February 28, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1125345/000119312524247017/0001193125-24-247017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.